Calling the Antibody Drug Conjugate Community!

2021 has proven an important year for the ADC community with:

The approvals of Zynlonta and Tivdak

PADCEV being granted regular approval

10 ADCs are currently being developed in pivotal trials or phase 3 development

14 other ADCs entering the clinic

The field is only going in one direction and that’s up, and very quickly at that.

However, understanding the best potency payload to use, the causes of off-target toxicity, scaling process and manufacturing capacities to deal with demand, patient selection and the strategic competition between commercially available ADCs are some of the aspects of the field keeping ADC developers awake at night.

It is vital for the community to come together to:

  • Nourish current pipelines of ADCs through improved preclinical understanding of PK/PD, developing more clinically relevant animal models, optimising dosing schedules and regimens in humans and harnessing biomarkers for improved patient selection and clinical outcomes
  • Develop the next generation of ADCs as we explore new payloads with new mechanisms of action, new linker-payload combinations as well as non-traditional ADCs including immune-stimulating-drug conjugates, radioimmunoconjugates, small-molecule drug conjugates and beyond
  • Confidently define your manufacturing processes by forging a strong CDMO relationship, effectively scaling up process to supply early clinical, late clinical and commercial demand, developing improved analytical methods to ensure purity and consistency and understanding the key CMC regulatory considerations

Reunite with the ADC community in London to exchange novel ideas, gather lessons learned and develop new partnerships to power another 12 months of transformative ADC research.

Complete Your 4-day World ADC Europe Experience

                  Seminar Days                      29th March



Introduction to ADCs

If you are new to the ADC field or are an emerging biotech, join this one-day intensive learning environment to establish core skills in ADC design, site specific conjugation, target selection and preclinical models to support early stage clinical trials.

3rd CMC Day

Your opportunity for a deep dive into all things CMC and manufacturing from Phase II through to commercial supply. Learn from experienced peers on scale-up, assay validation and important QA & QC reporting requirements for later clinical and commercial ADC manufacturing

2nd ADCs & Beyond; Non-Traditional ADCs

Explore novel format ADCs which include a targeting agent, a linker and a payload, however one aspect differs to the traditional ADC. Here we will be showcasing the state of the science and recent advances.

2 Scientific Programme Days   30-31st March


With four streams and 50+ speakers, check out the NEW Clinical Lessons Track!

To provide a complete end-to-end coverage of ADC development and to make World ADC London your one-stop-shop for all things ADC, this new addition will showcase recent clinical updates, but with a specific focus on what lessons were learned, to transform your clinical strategy and lead to more successful trials in the future.

Our four tracks ensure that we support your entire team with comprehensive insights across:

  1. Discovery
  2. Translational
  3. Clinical Lessons
  4. CMC

Bring your team so that you don’t miss out on any content and can fully benefit from the diverse insights being shared.


                 Workshop Day                   1st April


Get involved with our intimate discussion-based workshop sessions with fellow ADC developers who are also facing the same challenges as your team.

Take your pick of 9 revitalised workshops including:

Academic-Industry Collaborations to Progress ADC Development

Advancing Analytical Methods to Better Characterise Your ADC

Occupational Health & Safety Within ADC Projects


These interactive sessions also provide you with a platform to collaboratively discuss with your peers and ask your pressing questions to our expert workshop leaders.